---
id: competitor-pulseguard-medical
title: "PulseGuard Medical"
type: competitor
namespace: competitive
summary: "Adjacent fictional competitor; alternative architecture (in-clinic placement, in-home pad change); one 510(k) clearance frequently used as predicate."
auto_inject: false
applicable_when: null
confidence: 0.8
verified_at: 2026-05-21
verified_by: nemock
staleness_signal: "Refresh after any new PulseGuard 510(k) or material website change."
tags: [competitor, adjacent]
legal_name: "PulseGuard Medical Devices LLC"
canonical_url: "https://pulseguard-medical.example.com"
edges:
  - target: indication-for-use-pulseguard-rhythm-2022-q4
    type: related_to
    weight: 0.9
    note: "Current cleared IFU."
  - target: regulatory-clearance-K221567-pulseguard-rhythm
    type: related_to
    weight: 0.9
    note: "Cleared 510(k); commonly cited as predicate by other MCT filings."
related: []
source_url: null
controlled_document: false
---

# PulseGuard Medical

## Summary

A fictional adjacent competitor with a single cleared product. Their device is placed in-clinic by a technician and the patient self-changes pads at home — a hybrid model between clinic-placed and patient-applied wearables.

## Content

Positioning: "Clinically-placed, patient-managed cardiac monitoring." Their differentiator is the clinic placement step, which they argue produces better sensor placement and lower re-application rates than fully patient-applied devices.

PulseGuard's K221567 clearance has been cited as a predicate in multiple MCT 510(k) filings, including CardioTrace's K231234 and our planned K243189. It is a structurally important node in the competitive landscape even though the company is smaller than CardioTrace.

## Edges

Only two outbound edges because we know less about PulseGuard than CardioTrace. The schema accommodates uneven competitor depth — sparser doesn't mean wrong.

## Notes

Strategic question (not captured as a question node yet, but worth flagging): does PulseGuard's clinic-placement step represent a service-delivery moat that we are choosing not to compete on? Currently `decision-002-prescription-only-not-otc` covers our Rx-only position, but does not address clinic placement vs. patient self-application explicitly. This is fine for v1; flag if it comes up again.
